Should I buy AstraZeneca shares today?

AstraZeneca shares have moved higher over several years, but I think there’s a powerful reason for me to invest in the stock now.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Ten years ago, buying AstraZeneca (LSE: AZN) shares was a difficult decision for many investors. Back then, the pharmaceutical company’s earnings were weak and growth seemed elusive. 

All the talk was of a ‘patent cliff’. And that meant lots of the firm’s high-earning brands were timing-out of patent protection. And generic competition flooded the market causing AstraZeneca’s profits to plunge.

Earnings did a handbrake turn

For years, the company posted decreases in earnings instead of rises. Even as late as 2018 they plunged by almost 40%. But that marked the end of the company’s long period of purgatory. And the following year saw rocketing earnings up more than 70%. Happily, there’s been a rise every year since with City analysts predicting more ahead.

But despite all AstraZeneca’s sufferings on the earnings front, the share price has trended up since the beginning of 2013. And savvy investors saw it coming, such as Neil Woodford (yes, that Neil Woodford but when he was still great). 

Key to seeing the potential in AstraZeneca was to look below the surface of weak earnings. And specifically, to appreciate the strength and value of the company’s research and development (R&D) pipeline. I remember lots of analysts comparing AstraZeneca to GlaxoSmithKline (now GSK) back then. And AstraZeneca came out on top.

However, it’s hard to see into the ‘black box’ of a company’s R&D pipeline. And shareholders had to keep the faith. But those that did have been well rewarded, so far. The pipeline started spewing out new medicines and treatments and most sold in the market. Earnings received the long-awaited boost they needed. And the business has been flying ever since. Indeed, there’s been an annual double-digit percentage rise in earnings every year, starting from 2019.

The positive R&D spiral

Looking ahead, analysts expect an almost 200% uplift in the current year and nearly 16% in 2023. And the share price has risen to reflect all the progress. In 2012, I could have bought some of the shares for about 3,010p. But today they change hands for around 10,900p. That’s a gain of almost 265% — not bad for a sleepy FTSE 100 giant.

So, is it too late for me to buy AstraZeneca shares today? I don’t think so. The company is still pumping millions into its R&D activities and that, for me, is a powerful reason to buy some of the shares. July’s half-year results report started with the headline: “Strong revenue performance and R&D success enables further investment in the pipeline and new launches.” So, it looks like a case of success begets success in a kind of positive upward spiral.

However, there can be no certainty that R&D efforts will lead to blockbuster drugs. And it’s easy for any company to miss its earnings estimates because of operational setbacks and challenges.

Nevertheless, I’m tempted to tuck away some AstraZeneca shares now to hold for the long term as part of my diversified stock portfolio. And while I’m waiting for further operational progress to unfold, there’s a rising dividend to collect. It’s yielding around 2.3% for 2023, according to analysts’ predictions. However, I’m kicking myself for not buying around 2016 when the yield was over 5%!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has recommended GSK plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »